In this review:
- Adding epcoritamab to rituximab-lenalidomide for relapsed/refractory FL
- Glofitamab or rituximab, plus GemOx, for relapsed/refractory DLBCL
- Bortezomib + RCD as first-line treatment in Waldenström macroglobulinaemia
- Interim PET-adapted de-escalation of chemotherapy for advanced stage classical HL
- Pirtobrutinib-venetoclax in previously treated Waldenström macroglobulinaemia
- LRTA ± combination chemotherapy in newly diagnosed DLBCL
- BMS-986458 for relapsed/ refractory NHL
- Longitudinal ctDNA dynamics during and after first-line LBCL therapy
- Fixed-duration vs. continuous treatment for previously untreated CLL
Please login below to download this issue (PDF)